Ex-Pfizer R&D chief bets on 'small' approach

The wags that write the Wall Street Journal's health blog delighted in pointing out that as chief of Pfizer's R&D, Peter Corr hardly covered himself in pharma glory. Will he do better helping run Celtic Therapeutics? The splashy equity group prospects for promising therapies and then shepherds them through final trials. Corr says it's all very opportunistic and flexible, everything that Pfizer isn't. "When you're running an organization of 14,000 people, you're not running projects," Corr told the Health Blog. "The key to R&D for me...is a very small group."

- read the report from the Wall Street Journal's health blog

Related Articles:
Celtic plots $1.5B equity funds to fuel biotech deals. Report
Pfizer hires new R&D chief, launches biotech center. Report
Troubled Pfizer blueprints biotech venture effort. Report

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.